An interventional study of Aldosterone circulation and Medication in Hypertension, Aldosteronemia and CYP11B1, sponsored by DejthidaNathaphong. Not yet recruiting at 1 site in Thailand. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by DejthidaNathaphong · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Hypertension with a site in Thailand — 7 open to participants now, 14 under way, 4 of them phase 3. Hypertension · Thailand.
Among the 46 studies in Hypertension with a site in Thailand, this one is the 27th largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2026, is one of 14 with no phase, reaches primary completion later than 8 of the 13 other live ones, and was the 44th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →7 of the 46 studies in Hypertension with a site in Thailand are open now. Recruiting first, the newest first:
Mahidol University · Sites in Thailand
Ages 18–59 · Healthy volunteers
Boehringer Ingelheim · Sites in Thailand, United States, Argentina and 48 more countries
Ages 18+
AstraZeneca · Sites in Thailand, United States, Argentina and 39 more countries
Ages 18+
Chinese University of Hong Kong · Sites in Thailand, China, Hong Kong and 4 more countries
Ages 18+ · Women only
DejthidaNathaphong · Sites in Thailand
Ages 18+
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 325 across the 34 interventional studies, 1,248 across the 12 observational. Of the 28 that completed or were terminated, 9 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 46 have an industry lead sponsor. The 10 most frequent:
DejthidaNathaphong is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
DejthidaNathaphong has 4 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
5 of the studies in Hypertension with a site in Thailand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00368095Rajavithi HospitalRajavithi Health Promotion Project (Population Base Cohort) | 2026-12 |
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07187596DejthidaNathaphongMortality Outcome of Controlled Hypertension | 2026-12-18 |
| NCT07760623DejthidaNathaphongCommon Carotid Artery-Renal Artery-Femoral Artery Survey for Hypertension | 2026-12-31 |
| NCT07748975DejthidaNathaphongDecode the Environment Variation of Targeted Aldosterone Inducer and siLencer | 2027-02-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Hypertension with a site in Thailand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical outcome to identify and analyze the epigenetic, phenotypic, protein variation, metabolites of CYP450 Family 11 Subfamily B, both 1 and 2, human-associated aldosterone protein release, and signaling inhibitory pathways post-aldosterone-mineralocorticoid interaction.
We will include clinical studies (RCTs, cohort, case-control/series/report) from fresh human specimens. We will exclude animal studies, studies generated from cell culture, and aldosterone synthesis.
To systematically review and synthesize the literature on the main 2 questions Question 1: Which environment induces CYP11B1 or CYP11B2 activation causing hyperaldosteronemia in hypertension patients? Question 2: Which intracellular signal silences aldosterone-MR activity? For Individual Participant Data Meta-analysis, data will be extracted from final analysis articles from the framework of the data selection process only; the effect measurement and multi-variable model meta-analysis will be performed.
Primary Objective1: to identify CYP450 Family 11 Subfamily B and Aldosterone in hypertension patients following; By structure ● Evidence confirms Epigenetic profile of CYP450 Family 11 Subfamily B, Aldosterone, Signal in hypertension patients, both random and treated from any DNA sequencing method Protein synthesis evidence of aldosterone protein induces hypertension from Western blot or LC-MS By function Metabolomic profile: the substrate or product refers to aldosterone interaction causing end-organ cell line dysfunction or impaired structure.
Inhibitory signaling profiling of hypertension patients compared to non-hypertension patients, which negatively feedback to CYP450 Family 11 Subfamily B or Aldosterone
Secondary Objective 2:
Sub-group analysis effect measurement following;
Secondary Objective 2:
● Sensitivity and specificity of outcomes of hypertension patients who underwent estimate substrate associated aldosterone circulation Plasma CYP450 Family 11 Subfamily B Urine CYP450 Family 11 Subfamily B Plasma Aldosterone (active form) Plasma Aldosterone (metabolite form) Urine Aldosterone
Primary Objective1: to identify CYP450 Family 11 Subfamily B and Aldosterone in hypertension patients following; By structure ● Evidence confirms Epigenetic profile of CYP450 Family 11 Subfamily B, Aldosterone, Signal in hypertension patients, both random and treated from any DNA sequencing method Protein synthesis evidence of aldosterone protein induces hypertension from Western blot or LC-MS By function Metabolomic profile: the substrate or product refers to aldosterone interaction causing end-organ cell line dysfunction or impaired structure.
Inhibitory signaling profiling of hypertension patients compared to non-hypertension patients, which negatively feedback to CYP450 Family 11 Subfamily B or Aldosterone
Secondary Objective 2:
Sub-group analysis effect measurement following;
Secondary Objective 2:
● Sensitivity and specificity of outcomes of hypertension patients who underwent estimate substrate associated aldosterone circulation Plasma CYP450 Family 11 Subfamily B Urine CYP450 Family 11 Subfamily B Plasma Aldosterone (active form) Plasma Aldosterone (metabolite form) Urine Aldosterone Axin-CK1-GSK3-APC-Beta-catenin complex
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Test: Aldosterone circulation · Drug: Medication · Procedure: Operation
Diagnostic Test: Aldosterone circulation · Drug: Medication · Procedure: Operation
Evidence of synthesis of aldosterone and/or degradation of inactive forms of aldosterone, which focuses on * CYP450 Family 11 Subfamily B * Aldosterone protein * Beta-catenin * Axin-CK1-GSK3-APC complex
Medical treatment that interferes with free aldosterone levels and reports systolic blood pressure deviation
The non-medical intervention includes MIS, Open surgery, and intravascular guide treatment aim to treat hypetension and lower aldosterone level.
Aldosterone circulation profile
The result, both qualitative and quantitative, from aldosterone synthesis to degradation and elimination via urine.
Time frame: 12 months
Aldoseterone synthesis profile
Focus on both quantitative and qualitative evidence of aldosterone, CYP11B1, andand CYP11B2 protein
Time frame: 12 months
Degradation Profile
Focus on the ratio of degradation activity of the inactive form of aldosterone and the inhibitory competitor inhibits the cell product from the aldosterone-mineralocorticoid receptor. Axin-CK1-GSK3-APC complex profile is indicated
Time frame: 12 months
Plan to share: Yes — The recruitment is published data already
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Feb 2027, 2 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 2 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, last on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Medication
DejthidaNathaphong